In a strategic move aimed at strengthening its leading position in the healthcare sector in the Kingdom of Saudi Arabia, Middle East Healthcare Company (Saudi German Healthcare) announced a package of key decisions approved by the Board of Directors, which included the establishment of new business entities and a restructuring of the group’s executive leadership.
Establishing new companies to support expansion and growth
The Board of Directors, in its meeting held yesterday, approved the establishment of two wholly-owned limited liability companies, as part of the company's efforts to diversify its revenue streams and integrate its services. In an official statement published on the Saudi Stock Exchange (Tadawul) website, the company explained that the first company will be named "Saudi German Pharmaceutical Company" (Saudi German Pharmacies), with a capital of 100,000 riyals. Its activities will focus on operating and managing pharmacies, in addition to selling and distributing medicines and medical supplies, thus enhancing the group's ability to control the pharmaceutical supply chains for its hospitals and centers.
The second entity is the Saudi German Healthcare Company for Medical Care and Services, with a capital of one million Saudi riyals. This company will provide healthcare, support, and operational services, a move aimed at increasing operational efficiency and separating support services to ensure higher quality and a greater focus on core medical activity.
Appointing a new executive leadership and succession strategy
At the executive leadership level, the Board, based on the recommendation of the Nominations and Remuneration Committee, approved the appointment of Dr. Nizar Mohammed Sultan Bahabri as Group CEO, effective January 1, 2026 (12 Rajab 1447 AH). Dr. Bahabri, known for his extensive medical and administrative experience and his influential presence in the Saudi healthcare landscape, succeeds Dr. Ahmed Mohammed Shibl Al-Atris.
To ensure a smooth administrative transition, the company announced that Dr. Ahmed Al-Atris will continue in his position until the end of 2025, after which he will be appointed as a non-executive advisor to the company, reflecting the group’s keenness to benefit from accumulated expertise and ensure the stability of long-term strategic plans.
The economic context and the future of the health sector
These moves come at a time when the healthcare sector in Saudi Arabia is undergoing radical transformations as part of Vision 2030, which encourages the private sector to expand its investments and contribute effectively to the GDP. The move towards vertical integration (through the establishment of pharmaceutical and support services companies) is a globally adopted strategy for reducing operating costs and increasing profit margins.
The company confirmed that these steps come in support of its expansion strategy, noting that there is no material financial impact expected at the present time, and any subsequent developments will be announced in accordance with the applicable regulations, which gives a positive signal to investors about the sustainability of the company’s growth and the development of its governance.
